



ANTI- EPILEPTICS

Sources

- Bertram G. katzung Basic & Clinical
 Pharmacology 15th Edition
- Goodman and Gilman's The Pharmacological Basis of Therapeutics 13th edition





MOTTO AND VISION



- To impart evidence based research oriented medical education
- To provide best possible patient care
- To inculcate the values of mutual respect and ethical practice of medicine







4rd Year Pharmacology LGIS			
Core Subject – 60%			
Pharmacology			
Horizontal Integration – 10%			
Same Year Subjects	•	Eve	
Sume real Subjects		Pathology	
		rathology	
Vertical Integration – 10%			
Clinical Subjects	•	Medicine	
		Surgery	
Spiral Integration – 15%			
Different Year Basic Sciences	•	Physiology (10%)	
Subjects	•	Biochemistry (5%)	
Research & Bioethics, Digital library – 05%			

HORIZONTAL INTEGERATION-PATHOLOGY



Definition of Epilepsy



Epilepsy is a chronic neurological disorder characterized by recurrent seizures, which are <u>finite</u> episodes of brain dysfunction resulting from abnormal discharge of cerebral neurons.











- Epilepsy affects 0.5-1 % of the population
- The characteristic event is the seizure
- The seizure is caused by an abnormal highfrequency discharge of a group of neurons and spreading to a varying extent to affect other parts of the brain.
- No specific cause
- 1/3rd cases--- familial, involve genetic mutation



Normal Synaptic Transmission



Actions of Antiepileptic Drugs



- 8. Mg⁺⁺



CORE SUBJECT







- Inhibit repetitive activity
 - Blocking voltage gated Na channels (inhibition of high frequency firing is thought to be mediated by reducing ability of Na channels to recover from inactivation)
 - Blocking voltage gated Ca channels (Drugs effective against absence seizure work by inhibition of voltage-activated Ca²⁺ channels responsible for T-type Ca²⁺ currents.)





• Stabilizing membrane

Increased conductance through K conductance





- Increasing inhibitory output (GABA enhancers)
 - Increasing synthesis of GABA
 - Decreasing the degradation of GABA
 - Decreasing GABA uptake
 - GABA facilitators (GABAmimetics)
- Decreasing excitatory output (glutamic acid)
 Antagonism at Glutamic acid receptors





- Other non-specific mechanisms:
 - Inhibition of release of NE , serotinin
 - Increase uptake of dopamine
 - Inhibiton of Na /K ATPase
- Carbonic anhydrase inhibition







- On basis of their Chemistry
- On basis of therapeutic uses
- On basis of their mechanism of action

Chemical classification

- Hydantoins- phenytoin , mephenytoin , ethotin
- Barbiturates phenobarbitone , primidone
- Benzodiazepines diazepam , lorazepam , clonazepam , nitrazepam
- **Succinamides-** ethosuxamide , phensuxamide , methosuxamide
- Carboxylic acid- valproic acid , Na valproate
- Imminostilbenes- carbamazepine , oxcarbamazepine
- Sulfonamide derivatives- zonisamide , rufinamide
- **Oxazolindinediones** dimethadione , trimethadione
- **CA inhibitors-** acetazolamide , sulthiame
- GABA inhibitors- vigabatrin , gabapentin , pregablin
- Misc.- tiagabine , lamotrigine



Classification-mechanism of action

Na channel blockers

- Phenytoin
- Carbamazepine
- Valproic acid
- Topiramate
- Lacosamide

fosphenytoin Oxcarbamazepine Na valproate lamotrigine zonisamide

Ca channel blocker

- Phenytoin
- Ethosuxamide
- Lamotrigine

valproic acid barbiturates zonisamide







GABA enhancers



– Increase synthesis

- Valproic acid gabapentin
- Decrease degradation
 - Valproic acid vigabatrin gabapentin tiagabine
- Decrease uptake
 - Tiagabine gabapentin valproic acid
- Increase release/ GABA facilitators
 - Phenytoin phenobarbitone topiramate
 BZD

- Glutamate antagonists
 - Phenobarbitone
 - Phenytoin
 - Lamotirigine
 - Topiramate
 - Felbamate

• Carbonic anhydrase inhibitors

- Acetazolamide
- Topiramate





PROLONGATION OF Na⁺ CHANNEL INACTIVATION Phenytoin Carbamazepine Valproate Lamotrigine Topiramate Zonisamide

FACILITATION OF GABA MEDIATED CI CHANNEL OPENING Barbiturate (Barb.) Benzodiazepine (Bzd.) Vigabatrin (Viga.) Valproate (Valpr.) Gabapentin (Gabp.) Tiagabine (Tiag.) INHIBITION OF 'T' TYPE Ca²⁺ CURRENT Ethosuximide Trimethadione Valproate

Fig. 30.2: Major mechanisms of anticonvulsant action m: Activation gate; h: Inactivation gate; GABA-T: GABA transaminase; SSA: Succinic semialdehyde; GAT-1: GABA transporter

Pharmacokinetics of anti-seizure drugs – (in general)

- Most have oral activity
- All enter CNS
- 80-100% bioavailability
- Cleared chiefly by liver
- Many drugs are potent inducers of hepatic enzymes
- Mostly Administered in O.D / B.D doses



Phenytoin



Mechanism of Action:

- (1) Blocking voltage-dependence Na⁺ channel
- (2) Blocking voltage-dependence Ca²⁺ channel
- (3) Inhibiting calcium-induced secretory processes, including release of neurotransmitters(NE, SEROTININ)
- (4) Inhibiting GLUTAMATE action & potentiates GABA

Also promotes uptake of dopamine



Therapeutic uses



- Antiseizure:
 - grand mal epilepsy
 - tonic-clonic seizure disorders
 - Status epilepticus



• Can Treat trigeminal neuralgia

• Antiarrhythmic class IB- digitalis induced



Adverse effects of Phenytoin

- Nystagmus, Diplopia, Ataxia
- Gingival hyperplasia
- Hirsutism
- Increased collagen proliferation
- Hepatitis
- Fetal malformations: fetal hydantion syndrome
- Megaloblastic anemia
- Osteomalacia



Drug interactions of phenytoin:





- Phenobarbitone & carbamazepine increased plasma concentrations of phenytoin
- Izoniazide inhibit its metabolism
- Sulphonamide, phenylbutazone & valproic acid displace phenytoin from plasma protein binding
- Sucralfate binds phenytoin , decrease absorption

• MOA:

blocks Na channels



- Uses:
- Drug of choice in-
 - complex partial seizures (psychomotor epilepsy)
 - trigeminal neuralgia
 - Mania (alternative to lithium)







Carbamazepine

Carbamazepine-adverse effects &



interactions



- GIT disturbances
- Sedation and drowsiness
- Diplopia and ataxia
- Hyponatremia and water retention
- Aplastic anemia and agranulocytosis
- Increased rate of metabolism of phenytoin, ethosuximide, valporic acid and clonazepam
- Valporic acid may inhibit carbamazepine clearance



RESEARCH/ AI/BIOETHICS



- Mobed A, Shirafkan M, Charsouei S, Sadeghzadeh J, Ahmadalipour A. Biosensors technology for anti-epileptic drugs. Clinica Chimica Acta. 2022 Aug 1;533:175-82.
- Obaidullah AJ, Almehizia AA. Analysis experimental and modeling of the solubility of an antiepileptic drug, Levetiracetam, in supercritical solvent. Journal of Molecular Liquids. 2023 Nov 15;390:123065.
- Ammendolia I, Mannucci C, Cardia L, Calapai G, Gangemi S, Esposito E, Calapai F. Pharmacovigilance on cannabidiol as an antiepileptic agent. Frontiers in Pharmacology. 2023 Feb 10;14:1091978.

How to use HEC Digital Library

1. Go to the website of HEC National Digital Library

http://www.digitallibrary.edu.pk

REDICAL UNITED CAL UNITED CAL

- 2. On Home Page, click on the INSTITUTES.
- 3. A page will appear showing the universities from Public and Private Sector and other Institutes which have access to HEC National Digital Library (HNDL).
- 4. Select your desired Institute.
- 5. A page will appear showing the resources of the institution
- 6. Journals and Researches will appear
- 7. You can find a Journal by clicking on JOURNALS AND DATABASE and enter a keyword to search for your desired journal.



EOLA



- A patient with epilepsy is started on Phenytoin and experiences a rash, fever, and lymphadenopathy. What is the suspected diagnosis?
- A) Hypersensitivity reaction
- B) Toxic epidermal necrolysis
- C) Stevens-Johnson syndrome
- D) Drug-induced lupus
- E) Viral infection



EOLA



- A patient with epilepsy is taking Phenytoin and warfarin concurrently. What is the expected effect on warfarin's anticoagulant activity?
- A) Increased
- B) Decreased
- C) Unchanged
- D) Variable
- E) Reversible

